Interpretation of 2023 American Heart Association guideline for the management of patients with cardiac arrest or life-threatening toxicity due to poisoning (Ⅱ): management of cardiovascular substances poisoning_West China Medical Journal

Authors：

LIAO Dengyong ^1,2 , CHU Lili ^1,2 , YAO Peng ^1,2 , XIE Xuxin ^1,2 , PENG Aihua ^1,2 ,  CAO Yu ^1,2

1. Department of Emergency Medicine and Institute of Disaster Medicine, Institute of Emergency Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;
2. Disaster Medical Center, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding author：

CAO Yu, Email: yuyuer@126.com

Keywords：

Guideline; poisoning; cardiac arrest; cardiovascular drug; resuscitation

DOI：

10.7507/1002-0179.202409126

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

On September 18th, 2023, the American Heart Association published clinical management guidelines for patients with poisoning-induced cardiac arrest and critical cardiovascular illness in Circulation. Considering the important role of the guidelines in clinical practice, our team has divided them into three sections for detailed interpretation based on the different toxic effects of the drugs. This article is the second part of the interpretation, which combines the literature to interpret the recommendations related to cardiotoxic substance poisoning in the guidelines, mainly involving the clinical management of beta blockers, calcium channel blockers, digoxin and other cardiac glycosides, as well as sodium channel blocker poisoning, aiming to assist colleagues in their clinical practice through a detailed explanation of the key recommendations in the guidelines.

1.	Lavonas EJ, Akpunonu PD, Arens AM, et al. 2023 American Heart Association focused update on the management of patients with cardiac arrest or life-threatening toxicity due to poisoning: an update to the American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation, 2023, 148(16): e149-e184.
2.	向昕杰, 褚莉莉, 姚鹏, 等. 2023 年美国心脏协会中毒所致心脏骤停及心脏危重症管理指南解读(一):神经系统毒性物质中毒的管理. 华西医学, 2023, 38(11): 1616-1624.
3.	Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ, 1999, 318(7200): 1730-1737.
4.	Cruickshank JM. Beta blockers in hypertension. Lancet, 2010, 376(9739): 415, author reply 415-416.
5.	Borlaug BA, Omote K. Beta-blockers and exercise hemodynamics in hypertrophic cardiomyopathy. J Am Coll Cardiol, 2022, 79(16): 1576-1578.
6.	Balligand JL. β-adrenergic receptors cooperate with transcription factors: the “STAT” of their union. Circulation, 2016, 133(1): 4-7.
7.	Barnes PJ. Beta-adrenergic receptors and their regulation. Am J Respir Crit Care Med, 1995, 152(3): 838-860.
8.	DeWitt CR, Waksman JC. Pharmacology, pathophysiology and management of calcium channel blocker and beta-blocker toxicity. Toxicol Rev, 2004, 23(4): 223-238.
9.	Rotella JA, Greene SL, Koutsogiannis Z, et al. Treatment for beta-blocker poisoning: a systematic review. Clin Toxicol (Phila), 2020, 58(10): 943-983.
10.	Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation, 2019, 140(8): e382-e482.
11.	Holger JS, Stellpflug SJ, Cole JB, et al. High-dose insulin: a consecutive case series in toxin-induced cardiogenic shock. Clin Toxicol (Phila), 2011, 49(7): 653-658.
12.	Xu J, Qin X, Cai X, et al. Mitochondrial JNK activation triggers autophagy and apoptosis and aggravates myocardial injury following ischemia/reperfusion. Biochim Biophys Acta, 2015, 1852(2): 262-270.
13.	Lazzarin T, Tonon CR, Martins D, et al. Post-cardiac arrest: mechanisms, management, and future perspectives. J Clin Med, 2022, 12(1): 259.
14.	Iliadis F, Kadoglou N, Didangelos T. Insulin and the heart. Diabetes Res Clin Pract, 2011, 93(Suppl 1): S86-S91.
15.	Yuan TH, Kerns WP 2nd, Tomaszewski CA, et al. Insulin-glucose as adjunctive therapy for severe calcium channel antagonist poisoning. J Toxicol Clin Toxicol, 1999, 37(4): 463-474.
16.	Page CB, Ryan NM, Isbister GK. The safety of high-dose insulin euglycaemia therapy in toxin-induced cardiac toxicity. Clin Toxicol (Phila), 2018, 56(6): 389-396.
17.	Estall JL, Drucker DJ. Glucagon and glucagon-like peptide receptors as drug targets. Curr Pharm Des, 2006, 12(14): 1731-1750.
18.	Farah A, Tuttle R. Studies on the pharmacology of glucagon. J Pharmacol Exp Ther, 1960, 129: 49-55.
19.	Lucchesi BR. Cardiac actions of glucagon. Circ Res, 1968, 22(6): 777-787.
20.	Lvoff R, Wilcken DE. Glucagon in heart failure and in cardiogenic shock. Experience in 50 patients. Circulation, 1972, 45(3): 534-542.
21.	Boyd R, Ghosh A. Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Glucagon for the treatment of symptomatic beta blocker overdose. Emerg Med J, 2003, 20(3): 266-267.
22.	Zeljković I, Bulj N, Kolačević M, et al. Failure of intracardiac pacing after fatal propafenone overdose: a case report. J Emerg Med, 2018, 54(4): e65-e68.
23.	Bouchard J, Shepherd G, Hoffman RS, et al. Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup. Crit Care, 2021, 25(1): 201.
24.	Daubin C, Lehoux P, Ivascau C, et al. Extracorporeal life support in severe drug intoxication: a retrospective cohort study of seventeen cases. Crit Care, 2009, 13(4): R138.
25.	Duburcq T, Goutay J, Preau S, et al. Venoarterial extracorporeal membrane oxygenation in severe drug intoxication: a retrospective comparison of survivors and nonsurvivors. ASAIO J, 2022, 68(7): 907-913.
26.	Hayes BD, Gosselin S, Calello DP, et al. Systematic review of clinical adverse events reported after acute intravenous lipid emulsion administration. Clin Toxicol (Phila), 2016, 54(5): 365-404.
27.	Levine M, Skolnik AB, Ruha AM, et al. Complications following antidotal use of intravenous lipid emulsion therapy. J Med Toxicol, 2014, 10(1): 10-14.
28.	Elkayam U, Shotan A, Mehra A, et al. Calcium channel blockers in heart failure. J Am Coll Cardiol, 1993, 22(4 Suppl A): 139A-144A.
29.	Levine M, Curry SC, Padilla-Jones A, et al. Critical care management of verapamil and diltiazem overdose with a focus on vasopressors: a 25-year experience at a single center. Ann Emerg Med, 2013, 62(3): 252-258.
30.	Cole JB, Arens AM, Laes JR, et al. High dose insulin for beta-blocker and calcium channel-blocker poisoning. Am J Emerg Med, 2018, 36(10): 1817-1824.
31.	Schult RF, Nacca N, Grannell TL, et al. Evaluation of high-dose insulin/euglycemia therapy for suspected β-blocker or calcium channel blocker overdose following guideline implementation. Am J Health Syst Pharm, 2022, 79(7): 547-555.
32.	Howarth DM, Dawson AH, Smith AJ, et al. Calcium channel blocking drug overdose: an Australian series. Hum Exp Toxicol, 1994, 13(3): 161-166.
33.	Ramoska EA, Spiller HA, Winter M, et al. A one-year evaluation of calcium channel blocker overdoses: toxicity and treatment. Ann Emerg Med, 1993, 22(2): 196-200.
34.	Hofer CA, Smith JK, Tenholder MF. Verapamil intoxication: a literature review of overdoses and discussion of therapeutic options. Am J Med, 1993, 95(4): 431-438.
35.	Yao LF, MacLeod KM, McNeill JH. Glucagon-induced densensitization: correlation between cyclic AMP levels and contractile force. Eur J Pharmacol, 1982, 79(1/2): 147-150.
36.	St-Onge M, Dubé PA, Gosselin S, et al. Treatment for calcium channel blocker poisoning: a systematic review. Clin Toxicol (Phila), 2014, 52(9): 926-944.
37.	Warrick BJ, Tataru AP, Smolinske S. A systematic analysis of methylene blue for drug-induced shock. Clin Toxicol (Phila), 2016, 54(7): 547-555.
38.	Cole JB, Olives TD, Ulici A, et al. Extracorporeal membrane oxygenation for poisonings reported to U.S. Poison Centers from 2000 to 2018: an analysis of the National Poison Data System. Crit Care Med, 2020, 48(8): 1111-1119.
39.	Lewis J, Zarate M, Tran S, et al. The recommendation and use of extracorporeal membrane oxygenation (ECMO) in cases reported to the California Poison Control System. J Med Toxicol, 2019, 15(3): 169-177.
40.	Ramoska EA, Spiller HA, Myers A. Calcium channel blocker toxicity. Ann Emerg Med, 1990, 19(6): 649-653.
41.	Snover SW, Bocchino V. Massive diltiazem overdose. Ann Emerg Med, 1986, 15(10): 1221-1224.
42.	Doyon S, Roberts JR. The use of glucagon in a case of calcium channel blocker overdose. Ann Emerg Med, 1993, 22(7): 1229-1233.
43.	Smolinske S, Hoffman RS, Villeneuve E, et al. Utilization of lipid emulsion therapy in fatal overdose cases: an observational study. Clin Toxicol (Phila), 2019, 57(3): 197-202.
44.	Gosselin S, Hoegberg LC, Hoffman RS, et al. Evidence-based recommendations on the use of intravenous lipid emulsion therapy in poisoning. Clin Toxicol (Phila), 2016, 54(10): 899-923.
45.	Eddleston M, Warrell DA. Management of acute yellow oleander poisoning. QJM, 1999, 92(9): 483-485.
46.	Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med, 1997, 336(8): 525-533.
47.	Campbell TJ, MacDonald PS. Digoxin in heart failure and cardiac arrhythmias. Med J Aust, 2003, 179(2): 98-102.
48.	Patocka J, Nepovimova E, Wu W, et al. Digoxin: pharmacology and toxicology-a review. Environ Toxicol Pharmacol, 2020, 79: 103400.
49.	Bandara V, Weinstein SA, White J, et al. A review of the natural history, toxinology, diagnosis and clinical management of Nerium oleander (common oleander) and Thevetia peruviana (yellow oleander) poisoning. Toxicon, 2010, 56(3): 273-281.
50.	Rouault E, Ghnassia C, Filippi-Codaccioni E, et al. Dose and efficacy of repeated administrations of digoxin-specific antibody fragments: case report of foxglove poisoning. Basic Clin Pharmacol Toxicol, 2021, 128(1): 183-186.
51.	Wermuth ME, Vohra R, Bowman N, et al. Cardiac toxicity from intentional ingestion of pong-pong seeds (Cerbera Odollam). J Emerg Med, 2018, 55(4): 507-511.
52.	Wu IL, Yu JH, Lin CC, et al. Fatal cardiac glycoside poisoning due to mistaking foxglove for comfrey. Clin Toxicol (Phila), 2017, 55(7): 670-673.
53.	Bernshteyn M, Adams SH, Gada K. A case of attempted suicide by cerbera odollam seed ingestion. Case Rep Crit Care, 2020, 2020: 7367191.
54.	Chhabra N, Valento M, Bryant SM, et al. Digoxin-specific antibody fragment dosing: a case series. Am J Ther, 2016, 23(6): e1597-e1601.
55.	Hauptman PJ, Blume SW, Lewis EF, et al. Digoxin toxicity and use of digoxin immune fab: insights from a national hospital database. JACC Heart Fail, 2016, 4(5): 357-364.
56.	Chan BS, Buckley NA. Digoxin-specific antibody fragments in the treatment of digoxin toxicity. Clin Toxicol (Phila), 2014, 52(8): 824-836.
57.	Antman EM, Wenger TL, Butler VP, et al. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. Circulation, 1990, 81(6): 1744-1752.
58.	Bilbault P, Oubaassine R, Rahmani H, et al. Emergency step-by-step specific immunotherapy in severe digoxin poisoning: an observational cohort study. Eur J Emerg Med, 2009, 16(3): 145-149.
59.	Lapostolle F, Borron SW, Verdier C, et al. Digoxin-specific Fab fragments as single first-line therapy in digitalis poisoning. Crit Care Med, 2008, 36(11): 3014-3018.
60.	Schaeffer TH, Mlynarchek SL, Stanford CF, et al. Treatment of chronically digoxin-poisoned patients with a newer digoxin immune fab--a retrospective study. J Am Osteopath Assoc, 2010, 110(10): 587-592.
61.	Smolarz A, Roesch E, Lenz E, et al. Digoxin specific antibody (Fab) fragments in 34 cases of severe digitalis intoxication. J Toxicol Clin Toxicol, 1985, 23(4/5/6): 327-340.
62.	Woolf AD, Wenger TL, Smith TW, et al. Results of multicenter studies of digoxin-specific antibody fragments in managing digitalis intoxication in the pediatric population. Am J Emerg Med, 1991, 9(2 Suppl 1): 16-20; discussion 33-34.
63.	Sanaei-Zadeh H, Valian Z, Zamani N, et al. Clinical features and successful management of suicidal digoxin toxicity without use of digoxin-specific antibody (Fab) fragments--is it possible?. Trop Doct, 2011, 41(2): 108-110.
64.	Eddleston M, Rajapakse S, Rajakanthan, et al. Anti-digoxin Fab fragments in cardiotoxicity induced by ingestion of yellow oleander: a randomised controlled trial. Lancet, 2000, 355(9208): 967-972.
65.	Combe C, Guitton J, Daudé A, et al. Multidisciplinary management of voluntary pink oleander poisoning: how to estimate the quantities ingested?. Ann Pharm Fr, 2022, 80(1): 76-80.
66.	Hansen LL, Herskind AM. Digoxin intoxication in an infant because of confusion of bottles of magistral preparations of medicine. Ugeskr Laeger, 2014, 176(30): V12130715.
67.	Chi HT, Hung DZ, Hu WH, et al. Prognostic implications of hyperkalemia in toad toxin intoxication. Hum Exp Toxicol, 1998, 17(6): 343-346.
68.	Aeberhard P, Butler VP, Smith TW, et al. Treatment of massive digitalis poisoning (20 mg of digitoxin) with anti-digoxin antibody fragments (Fab). Arch Mal Coeur Vaiss, 1980, 73(12): 1471-1478.
69.	Brown JH, McLoughlin JC, Boland M. Use of digoxin-specific antibody fragments (Fab) in the management of digoxin poisoning. Ulster Med J, 1986, 55(1): 89-92.
70.	Delva P. Magnesium and cardiac arrhythmias. Mol Aspects Med, 2003, 24(1/2/3): 53-62.
71.	Nicholls DP, Murtagh JG, Holt DW. Use of amiodarone and digoxin specific Fab antibodies in digoxin overdosage. Br Heart J, 1985, 53(4): 462-464.
72.	Alarfaj M, Goswami A. Cardiotoxicity in yew berry poisoning. Am J Emerg Med, 2021, 50: 812.e1-812.e4.
73.	Chen JY, Liu PY, Chen JH, et al. Safety of transvenous temporary cardiac pacing in patients with accidental digoxin overdose and symptomatic bradycardia. Cardiology, 2004, 102(3): 152-155.
74.	Vincent JL, Dufaye P, Berre J, et al. Bretylium in severe ventricular arrhythmias associated with digitalis intoxication. Am J Emerg Med, 1984, 2(6): 504-506.
75.	Battegay M, Cottier C, Burckhardt D, et al. Acute digitoxin poisoning. Schweiz Rundsch Med Prax, 1989, 78(33): 880-882.
76.	Rumack BH, Wolfe RR, Gilfrich H. Phenytoin (diphenylhydantoin) treatment of massive digoxin overdose. Br Heart J, 1974, 36(4): 405-408.
77.	Thind M, Sullivan RM, Williams RN, et al. Bretylium, a class III antiarrhythmic, returns to the market. Am J Cardiol, 2020, 133: 77-80.
78.	Mowry JB, Burdmann EA, Anseeuw K, et al. Extracorporeal treatment for digoxin poisoning: systematic review and recommendations from the EXTRIP Workgroup. Clin Toxicol (Phila), 2016, 54(2): 103-114.
79.	Hoffman JR, Votey SR, Bayer M, et al. Effect of hypertonic sodium bicarbonate in the treatment of moderate-to-severe cyclic antidepressant overdose. Am J Emerg Med, 1993, 11(4): 336-341.
80.	Bradberry SM, Thanacoody HK, Watt BE, et al. Management of the cardiovascular complications of tricyclic antidepressant poisoning : role of sodium bicarbonate. Toxicol Rev, 2005, 24(3): 195-204.
81.	Pai K, Buckley NA, Isoardi KZ, et al. Optimising alkalinisation and its effect on QRS narrowing in tricyclic antidepressant poisoning. Br J Clin Pharmacol, 2022, 88(2): 723-733.
82.	Mirrakhimov AE, Ayach T, Barbaryan A, et al. The role of sodium bicarbonate in the management of some toxic ingestions. Int J Nephrol, 2017, 2017: 7831358.
83.	Bruccoleri RE, Burns MM. A literature review of the use of sodium bicarbonate for the treatment of QRS widening. J Med Toxicol, 2016, 12(1): 121-129.
84.	Sasyniuk BI, Jhamandas V. Mechanism of reversal of toxic effects of amitriptyline on cardiac Purkinje fibers by sodium bicarbonate. J Pharmacol Exp Ther, 1984, 231(2): 387-394.
85.	Adrogué HJ, Awan AA, Madias NE. Determinants of hypokalemia following hypertonic sodium bicarbonate infusion. Pflugers Arch, 2022, 474(6): 603-612.
86.	Seger DL. A critical reconsideration of the clinical effects and treatment recommendations for sodium channel blocking drug cardiotoxicity. Toxicol Rev, 2006, 25(4): 283-296.
87.	Greene SL, Dargan PI, Jones AL. Acute poisoning: understanding 90% of cases in a nutshell. Postgrad Med J, 2005, 81(954): 204-216.
88.	Ramasubbu B, James D, Scurr A, et al. Serum alkalinisation is the cornerstone of treatment for amitriptyline poisoning. BMJ Case Rep, 2016, 2016: 10.1136/bcr-2016-214685.
89.	Blackman K, Brown SG, Wilkes GJ. Plasma alkalinization for tricyclic antidepressant toxicity: a systematic review. Emerg Med (Fremantle), 2001, 13(2): 204-210.
90.	Foianini A, Joseph Wiegand T, Benowitz N. What is the role of lidocaine or phenytoin in tricyclic antidepressant-induced cardiotoxicity?. Clin Toxicol (Phila), 2010, 48(4): 325-330.
91.	Hagerman GA, Hanashiro PK. Reversal of tricyclic-antidepressant-induced cardiac conduction abnormalities by phenytoin. Ann Emerg Med, 1981, 10(2): 82-86.
92.	Levine M, Brooks DE, Franken A, et al. Delayed-onset seizure and cardiac arrest after amitriptyline overdose, treated with intravenous lipid emulsion therapy. Pediatrics, 2012, 130(2): e432-e438.
93.	Le Fevre P, Gosling M, Acharya K, et al. Dramatic resuscitation with Intralipid in an epinephrine unresponsive cardiac arrest following overdose of amitriptyline and propranolol. BMJ Case Rep, 2017, 2017: bcr2016218281.
94.	Varney SM, Bebarta VS, Vargas TE, et al. Intravenous lipid emulsion therapy does not improve hypotension compared to sodium bicarbonate for tricyclic antidepressant toxicity: a randomized, controlled pilot study in a swine model. Acad Emerg Med, 2014, 21(11): 1212-1219.
95.	Masson R, Colas V, Parienti JJ, et al. A comparison of survival with and without extracorporeal life support treatment for severe poisoning due to drug intoxication. Resuscitation, 2012, 83(11): 1413-1417.
96.	Reynolds JC, Judge BS. Successful treatment of flecainide-induced cardiac arrest with extracorporeal membrane oxygenation in the ED. Am J Emerg Med, 2015, 33(10): 1542.e1-1542.e2.
97.	de Lange DW, Sikma MA, Meulenbelt J. Extracorporeal membrane oxygenation in the treatment of poisoned patients. Clin Toxicol (Phila), 2013, 51(5): 385-393.

1. Lavonas EJ, Akpunonu PD, Arens AM, et al. 2023 American Heart Association focused update on the management of patients with cardiac arrest or life-threatening toxicity due to poisoning: an update to the American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation, 2023, 148(16): e149-e184.
2. 向昕杰, 褚莉莉, 姚鹏, 等. 2023 年美国心脏协会中毒所致心脏骤停及心脏危重症管理指南解读(一):神经系统毒性物质中毒的管理. 华西医学, 2023, 38(11): 1616-1624.
3. Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ, 1999, 318(7200): 1730-1737.
4. Cruickshank JM. Beta blockers in hypertension. Lancet, 2010, 376(9739): 415, author reply 415-416.
5. Borlaug BA, Omote K. Beta-blockers and exercise hemodynamics in hypertrophic cardiomyopathy. J Am Coll Cardiol, 2022, 79(16): 1576-1578.
6. Balligand JL. β-adrenergic receptors cooperate with transcription factors: the “STAT” of their union. Circulation, 2016, 133(1): 4-7.
7. Barnes PJ. Beta-adrenergic receptors and their regulation. Am J Respir Crit Care Med, 1995, 152(3): 838-860.
8. DeWitt CR, Waksman JC. Pharmacology, pathophysiology and management of calcium channel blocker and beta-blocker toxicity. Toxicol Rev, 2004, 23(4): 223-238.
9. Rotella JA, Greene SL, Koutsogiannis Z, et al. Treatment for beta-blocker poisoning: a systematic review. Clin Toxicol (Phila), 2020, 58(10): 943-983.
10. Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation, 2019, 140(8): e382-e482.
11. Holger JS, Stellpflug SJ, Cole JB, et al. High-dose insulin: a consecutive case series in toxin-induced cardiogenic shock. Clin Toxicol (Phila), 2011, 49(7): 653-658.
12. Xu J, Qin X, Cai X, et al. Mitochondrial JNK activation triggers autophagy and apoptosis and aggravates myocardial injury following ischemia/reperfusion. Biochim Biophys Acta, 2015, 1852(2): 262-270.
13. Lazzarin T, Tonon CR, Martins D, et al. Post-cardiac arrest: mechanisms, management, and future perspectives. J Clin Med, 2022, 12(1): 259.
14. Iliadis F, Kadoglou N, Didangelos T. Insulin and the heart. Diabetes Res Clin Pract, 2011, 93(Suppl 1): S86-S91.
15. Yuan TH, Kerns WP 2nd, Tomaszewski CA, et al. Insulin-glucose as adjunctive therapy for severe calcium channel antagonist poisoning. J Toxicol Clin Toxicol, 1999, 37(4): 463-474.
16. Page CB, Ryan NM, Isbister GK. The safety of high-dose insulin euglycaemia therapy in toxin-induced cardiac toxicity. Clin Toxicol (Phila), 2018, 56(6): 389-396.
17. Estall JL, Drucker DJ. Glucagon and glucagon-like peptide receptors as drug targets. Curr Pharm Des, 2006, 12(14): 1731-1750.
18. Farah A, Tuttle R. Studies on the pharmacology of glucagon. J Pharmacol Exp Ther, 1960, 129: 49-55.
19. Lucchesi BR. Cardiac actions of glucagon. Circ Res, 1968, 22(6): 777-787.
20. Lvoff R, Wilcken DE. Glucagon in heart failure and in cardiogenic shock. Experience in 50 patients. Circulation, 1972, 45(3): 534-542.
21. Boyd R, Ghosh A. Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Glucagon for the treatment of symptomatic beta blocker overdose. Emerg Med J, 2003, 20(3): 266-267.
22. Zeljković I, Bulj N, Kolačević M, et al. Failure of intracardiac pacing after fatal propafenone overdose: a case report. J Emerg Med, 2018, 54(4): e65-e68.
23. Bouchard J, Shepherd G, Hoffman RS, et al. Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup. Crit Care, 2021, 25(1): 201.
24. Daubin C, Lehoux P, Ivascau C, et al. Extracorporeal life support in severe drug intoxication: a retrospective cohort study of seventeen cases. Crit Care, 2009, 13(4): R138.
25. Duburcq T, Goutay J, Preau S, et al. Venoarterial extracorporeal membrane oxygenation in severe drug intoxication: a retrospective comparison of survivors and nonsurvivors. ASAIO J, 2022, 68(7): 907-913.
26. Hayes BD, Gosselin S, Calello DP, et al. Systematic review of clinical adverse events reported after acute intravenous lipid emulsion administration. Clin Toxicol (Phila), 2016, 54(5): 365-404.
27. Levine M, Skolnik AB, Ruha AM, et al. Complications following antidotal use of intravenous lipid emulsion therapy. J Med Toxicol, 2014, 10(1): 10-14.
28. Elkayam U, Shotan A, Mehra A, et al. Calcium channel blockers in heart failure. J Am Coll Cardiol, 1993, 22(4 Suppl A): 139A-144A.
29. Levine M, Curry SC, Padilla-Jones A, et al. Critical care management of verapamil and diltiazem overdose with a focus on vasopressors: a 25-year experience at a single center. Ann Emerg Med, 2013, 62(3): 252-258.
30. Cole JB, Arens AM, Laes JR, et al. High dose insulin for beta-blocker and calcium channel-blocker poisoning. Am J Emerg Med, 2018, 36(10): 1817-1824.
31. Schult RF, Nacca N, Grannell TL, et al. Evaluation of high-dose insulin/euglycemia therapy for suspected β-blocker or calcium channel blocker overdose following guideline implementation. Am J Health Syst Pharm, 2022, 79(7): 547-555.
32. Howarth DM, Dawson AH, Smith AJ, et al. Calcium channel blocking drug overdose: an Australian series. Hum Exp Toxicol, 1994, 13(3): 161-166.
33. Ramoska EA, Spiller HA, Winter M, et al. A one-year evaluation of calcium channel blocker overdoses: toxicity and treatment. Ann Emerg Med, 1993, 22(2): 196-200.
34. Hofer CA, Smith JK, Tenholder MF. Verapamil intoxication: a literature review of overdoses and discussion of therapeutic options. Am J Med, 1993, 95(4): 431-438.
35. Yao LF, MacLeod KM, McNeill JH. Glucagon-induced densensitization: correlation between cyclic AMP levels and contractile force. Eur J Pharmacol, 1982, 79(1/2): 147-150.
36. St-Onge M, Dubé PA, Gosselin S, et al. Treatment for calcium channel blocker poisoning: a systematic review. Clin Toxicol (Phila), 2014, 52(9): 926-944.
37. Warrick BJ, Tataru AP, Smolinske S. A systematic analysis of methylene blue for drug-induced shock. Clin Toxicol (Phila), 2016, 54(7): 547-555.
38. Cole JB, Olives TD, Ulici A, et al. Extracorporeal membrane oxygenation for poisonings reported to U.S. Poison Centers from 2000 to 2018: an analysis of the National Poison Data System. Crit Care Med, 2020, 48(8): 1111-1119.
39. Lewis J, Zarate M, Tran S, et al. The recommendation and use of extracorporeal membrane oxygenation (ECMO) in cases reported to the California Poison Control System. J Med Toxicol, 2019, 15(3): 169-177.
40. Ramoska EA, Spiller HA, Myers A. Calcium channel blocker toxicity. Ann Emerg Med, 1990, 19(6): 649-653.
41. Snover SW, Bocchino V. Massive diltiazem overdose. Ann Emerg Med, 1986, 15(10): 1221-1224.
42. Doyon S, Roberts JR. The use of glucagon in a case of calcium channel blocker overdose. Ann Emerg Med, 1993, 22(7): 1229-1233.
43. Smolinske S, Hoffman RS, Villeneuve E, et al. Utilization of lipid emulsion therapy in fatal overdose cases: an observational study. Clin Toxicol (Phila), 2019, 57(3): 197-202.
44. Gosselin S, Hoegberg LC, Hoffman RS, et al. Evidence-based recommendations on the use of intravenous lipid emulsion therapy in poisoning. Clin Toxicol (Phila), 2016, 54(10): 899-923.
45. Eddleston M, Warrell DA. Management of acute yellow oleander poisoning. QJM, 1999, 92(9): 483-485.
46. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med, 1997, 336(8): 525-533.
47. Campbell TJ, MacDonald PS. Digoxin in heart failure and cardiac arrhythmias. Med J Aust, 2003, 179(2): 98-102.
48. Patocka J, Nepovimova E, Wu W, et al. Digoxin: pharmacology and toxicology-a review. Environ Toxicol Pharmacol, 2020, 79: 103400.
49. Bandara V, Weinstein SA, White J, et al. A review of the natural history, toxinology, diagnosis and clinical management of Nerium oleander (common oleander) and Thevetia peruviana (yellow oleander) poisoning. Toxicon, 2010, 56(3): 273-281.
50. Rouault E, Ghnassia C, Filippi-Codaccioni E, et al. Dose and efficacy of repeated administrations of digoxin-specific antibody fragments: case report of foxglove poisoning. Basic Clin Pharmacol Toxicol, 2021, 128(1): 183-186.
51. Wermuth ME, Vohra R, Bowman N, et al. Cardiac toxicity from intentional ingestion of pong-pong seeds (Cerbera Odollam). J Emerg Med, 2018, 55(4): 507-511.
52. Wu IL, Yu JH, Lin CC, et al. Fatal cardiac glycoside poisoning due to mistaking foxglove for comfrey. Clin Toxicol (Phila), 2017, 55(7): 670-673.
53. Bernshteyn M, Adams SH, Gada K. A case of attempted suicide by cerbera odollam seed ingestion. Case Rep Crit Care, 2020, 2020: 7367191.
54. Chhabra N, Valento M, Bryant SM, et al. Digoxin-specific antibody fragment dosing: a case series. Am J Ther, 2016, 23(6): e1597-e1601.
55. Hauptman PJ, Blume SW, Lewis EF, et al. Digoxin toxicity and use of digoxin immune fab: insights from a national hospital database. JACC Heart Fail, 2016, 4(5): 357-364.
56. Chan BS, Buckley NA. Digoxin-specific antibody fragments in the treatment of digoxin toxicity. Clin Toxicol (Phila), 2014, 52(8): 824-836.
57. Antman EM, Wenger TL, Butler VP, et al. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. Circulation, 1990, 81(6): 1744-1752.
58. Bilbault P, Oubaassine R, Rahmani H, et al. Emergency step-by-step specific immunotherapy in severe digoxin poisoning: an observational cohort study. Eur J Emerg Med, 2009, 16(3): 145-149.
59. Lapostolle F, Borron SW, Verdier C, et al. Digoxin-specific Fab fragments as single first-line therapy in digitalis poisoning. Crit Care Med, 2008, 36(11): 3014-3018.
60. Schaeffer TH, Mlynarchek SL, Stanford CF, et al. Treatment of chronically digoxin-poisoned patients with a newer digoxin immune fab--a retrospective study. J Am Osteopath Assoc, 2010, 110(10): 587-592.
61. Smolarz A, Roesch E, Lenz E, et al. Digoxin specific antibody (Fab) fragments in 34 cases of severe digitalis intoxication. J Toxicol Clin Toxicol, 1985, 23(4/5/6): 327-340.
62. Woolf AD, Wenger TL, Smith TW, et al. Results of multicenter studies of digoxin-specific antibody fragments in managing digitalis intoxication in the pediatric population. Am J Emerg Med, 1991, 9(2 Suppl 1): 16-20; discussion 33-34.
63. Sanaei-Zadeh H, Valian Z, Zamani N, et al. Clinical features and successful management of suicidal digoxin toxicity without use of digoxin-specific antibody (Fab) fragments--is it possible?. Trop Doct, 2011, 41(2): 108-110.
64. Eddleston M, Rajapakse S, Rajakanthan, et al. Anti-digoxin Fab fragments in cardiotoxicity induced by ingestion of yellow oleander: a randomised controlled trial. Lancet, 2000, 355(9208): 967-972.
65. Combe C, Guitton J, Daudé A, et al. Multidisciplinary management of voluntary pink oleander poisoning: how to estimate the quantities ingested?. Ann Pharm Fr, 2022, 80(1): 76-80.
66. Hansen LL, Herskind AM. Digoxin intoxication in an infant because of confusion of bottles of magistral preparations of medicine. Ugeskr Laeger, 2014, 176(30): V12130715.
67. Chi HT, Hung DZ, Hu WH, et al. Prognostic implications of hyperkalemia in toad toxin intoxication. Hum Exp Toxicol, 1998, 17(6): 343-346.
68. Aeberhard P, Butler VP, Smith TW, et al. Treatment of massive digitalis poisoning (20 mg of digitoxin) with anti-digoxin antibody fragments (Fab). Arch Mal Coeur Vaiss, 1980, 73(12): 1471-1478.
69. Brown JH, McLoughlin JC, Boland M. Use of digoxin-specific antibody fragments (Fab) in the management of digoxin poisoning. Ulster Med J, 1986, 55(1): 89-92.
70. Delva P. Magnesium and cardiac arrhythmias. Mol Aspects Med, 2003, 24(1/2/3): 53-62.
71. Nicholls DP, Murtagh JG, Holt DW. Use of amiodarone and digoxin specific Fab antibodies in digoxin overdosage. Br Heart J, 1985, 53(4): 462-464.
72. Alarfaj M, Goswami A. Cardiotoxicity in yew berry poisoning. Am J Emerg Med, 2021, 50: 812.e1-812.e4.
73. Chen JY, Liu PY, Chen JH, et al. Safety of transvenous temporary cardiac pacing in patients with accidental digoxin overdose and symptomatic bradycardia. Cardiology, 2004, 102(3): 152-155.
74. Vincent JL, Dufaye P, Berre J, et al. Bretylium in severe ventricular arrhythmias associated with digitalis intoxication. Am J Emerg Med, 1984, 2(6): 504-506.
75. Battegay M, Cottier C, Burckhardt D, et al. Acute digitoxin poisoning. Schweiz Rundsch Med Prax, 1989, 78(33): 880-882.
76. Rumack BH, Wolfe RR, Gilfrich H. Phenytoin (diphenylhydantoin) treatment of massive digoxin overdose. Br Heart J, 1974, 36(4): 405-408.
77. Thind M, Sullivan RM, Williams RN, et al. Bretylium, a class III antiarrhythmic, returns to the market. Am J Cardiol, 2020, 133: 77-80.
78. Mowry JB, Burdmann EA, Anseeuw K, et al. Extracorporeal treatment for digoxin poisoning: systematic review and recommendations from the EXTRIP Workgroup. Clin Toxicol (Phila), 2016, 54(2): 103-114.
79. Hoffman JR, Votey SR, Bayer M, et al. Effect of hypertonic sodium bicarbonate in the treatment of moderate-to-severe cyclic antidepressant overdose. Am J Emerg Med, 1993, 11(4): 336-341.
80. Bradberry SM, Thanacoody HK, Watt BE, et al. Management of the cardiovascular complications of tricyclic antidepressant poisoning : role of sodium bicarbonate. Toxicol Rev, 2005, 24(3): 195-204.
81. Pai K, Buckley NA, Isoardi KZ, et al. Optimising alkalinisation and its effect on QRS narrowing in tricyclic antidepressant poisoning. Br J Clin Pharmacol, 2022, 88(2): 723-733.
82. Mirrakhimov AE, Ayach T, Barbaryan A, et al. The role of sodium bicarbonate in the management of some toxic ingestions. Int J Nephrol, 2017, 2017: 7831358.
83. Bruccoleri RE, Burns MM. A literature review of the use of sodium bicarbonate for the treatment of QRS widening. J Med Toxicol, 2016, 12(1): 121-129.
84. Sasyniuk BI, Jhamandas V. Mechanism of reversal of toxic effects of amitriptyline on cardiac Purkinje fibers by sodium bicarbonate. J Pharmacol Exp Ther, 1984, 231(2): 387-394.
85. Adrogué HJ, Awan AA, Madias NE. Determinants of hypokalemia following hypertonic sodium bicarbonate infusion. Pflugers Arch, 2022, 474(6): 603-612.
86. Seger DL. A critical reconsideration of the clinical effects and treatment recommendations for sodium channel blocking drug cardiotoxicity. Toxicol Rev, 2006, 25(4): 283-296.
87. Greene SL, Dargan PI, Jones AL. Acute poisoning: understanding 90% of cases in a nutshell. Postgrad Med J, 2005, 81(954): 204-216.
88. Ramasubbu B, James D, Scurr A, et al. Serum alkalinisation is the cornerstone of treatment for amitriptyline poisoning. BMJ Case Rep, 2016, 2016: 10.1136/bcr-2016-214685.
89. Blackman K, Brown SG, Wilkes GJ. Plasma alkalinization for tricyclic antidepressant toxicity: a systematic review. Emerg Med (Fremantle), 2001, 13(2): 204-210.
90. Foianini A, Joseph Wiegand T, Benowitz N. What is the role of lidocaine or phenytoin in tricyclic antidepressant-induced cardiotoxicity?. Clin Toxicol (Phila), 2010, 48(4): 325-330.
91. Hagerman GA, Hanashiro PK. Reversal of tricyclic-antidepressant-induced cardiac conduction abnormalities by phenytoin. Ann Emerg Med, 1981, 10(2): 82-86.
92. Levine M, Brooks DE, Franken A, et al. Delayed-onset seizure and cardiac arrest after amitriptyline overdose, treated with intravenous lipid emulsion therapy. Pediatrics, 2012, 130(2): e432-e438.
93. Le Fevre P, Gosling M, Acharya K, et al. Dramatic resuscitation with Intralipid in an epinephrine unresponsive cardiac arrest following overdose of amitriptyline and propranolol. BMJ Case Rep, 2017, 2017: bcr2016218281.
94. Varney SM, Bebarta VS, Vargas TE, et al. Intravenous lipid emulsion therapy does not improve hypotension compared to sodium bicarbonate for tricyclic antidepressant toxicity: a randomized, controlled pilot study in a swine model. Acad Emerg Med, 2014, 21(11): 1212-1219.
95. Masson R, Colas V, Parienti JJ, et al. A comparison of survival with and without extracorporeal life support treatment for severe poisoning due to drug intoxication. Resuscitation, 2012, 83(11): 1413-1417.
96. Reynolds JC, Judge BS. Successful treatment of flecainide-induced cardiac arrest with extracorporeal membrane oxygenation in the ED. Am J Emerg Med, 2015, 33(10): 1542.e1-1542.e2.
97. de Lange DW, Sikma MA, Meulenbelt J. Extracorporeal membrane oxygenation in the treatment of poisoned patients. Clin Toxicol (Phila), 2013, 51(5): 385-393.

West China Medical Journal

Latest ArticlesInterpretation of 2023 American Heart Association guideline for the management of patients with cardiac arrest or life-threatening toxicity due to poisoning (Ⅱ): management of cardiovascular substances poisoning

Abstract Full text Figures/Tables Video References Cited by

Format

Content